Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

The move halts several pilot programs, including offering Medicare Part D recipients generic medications for a $2 copay.

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the ...

Respondents agreed that the level of risk in pharmaceutical supply chains has increased across the board since 2023, although perceptions about the degree of escalation vary. Fifty-six (56%) percent ...

In the tough market conditions last year, investors and big pharma companies were more likely to place their bets on later, ...

With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.

Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...

Medicare to negotiate prices for Ozempic, Wegovy, and 13 other drugs, potentially saving billions for taxpayers.

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.